Bristol-Myers Squibb: I See No Catalysts To Break Underperformance (NYSE:BMY)

Bristol-Myers Squibb ( BMY ) is a company that was blessed with multiple early mega blockbuster therapies: Eliquis, Opdivo, and Revlimid (via Celgene). Sometimes, mega blockbusters are more of a curse than a blessing. They lead to tremendous financial fortune forHello, I am an individual investor with an interest in bringing diversification of viewpoints to stock analysis and investing. This brings to point the Japanese proverb 他山之石 -ta-zan-no-ishi- which translates to "another-mountain's-rock" and denotes ...